Skip to main content
SpringerLink
Log in

Immunotherapy of Parkinson’s Disease

  • Protocol
  • First Online:
Immunotherapy and Biomarkers in Neurodegenerative Disorders

Part of the book series: Methods in Pharmacology and Toxicology ((MIPT))

  • 946 Accesses

Abstract

Parkinson’s disease (PD) is the second most common neurodegenerative disorder. It elicits a broad range of debilitating motor and as well as non-motor symptoms, both of which can lead to serious disability. There is currently no available agent with disease modifying properties. Immunotherapy is increasingly being investigated as a disease modifying treatment for PD based on our improved understanding of the pathophysiology of the disease. Current evidence points to a causal role of misfolded alpha-synuclein (α-syn) in the development and progression of PD and it has therefore become a primary focus for immunotherapy. Today, two principal approaches are being pursued: active and passive immunization. This chapter first addresses progress in active and passive immunotherapeutic approaches targeting α-syn for Parkinson’s disease in animal models. We then discuss clinical progress of α-syn immunotherapy including ongoing clinical trials. Finally, we address challenges and future perspectives for PD immunotherapy.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Protocol
USD 49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Abbreviations

α-syn:

Alpha-synuclein

β-syn:

Beta-synuclein

DA:

Dopamine

DLB:

Dementia with Lewy bodies

DOPAC:

3,4-Dihydroxyphenylacetic acid

GCI:

Glial cytoplasmatic inclusions

h:

Human

HVA:

Homovanillic acid

LB:

Lewy body

mAb:

Monoclonal antibody

MSA:

Multiple system atrophy

PD:

Parkinson’s disease

PDD:

Parkinson’s disease dementia

REM:

Rapid eye movement

MWM:

Morris water maze

References

  1. Davie CA (2008) A review of Parkinson’s disease. Br Med Bull 86:109–127

    Article  CAS  PubMed  Google Scholar 

  2. Meissner WG, Frasier M, Gasser T et al (2011) Priorities in Parkinson’s disease research. Nat Rev Drug Discov 10(5):377–393

    Article  CAS  PubMed  Google Scholar 

  3. Parkinson J (2002) An essay on the shaking palsy. 1817. J Neuropsychiatry Clin Neurosci 14(2):223–236, discussion 222

    Article  PubMed  Google Scholar 

  4. Dubois B, Tolosa E, Katzenschlager R et al (2012) Donepezil in Parkinson’s disease dementia: a randomized, double-blind efficacy and safety study. Mov Disord 27(10):1230–1238

    Article  CAS  PubMed  Google Scholar 

  5. Dauer W, Przedborski S (2003) Parkinson’s disease: mechanisms and models. Neuron 39(6):889–909

    Article  CAS  PubMed  Google Scholar 

  6. Spillantini MG, Schmidt ML, Lee VM et al (1997) Alpha-synuclein in Lewy bodies. Nature 388(6645):839–840

    Article  CAS  PubMed  Google Scholar 

  7. Kosaka K (1978) Lewy bodies in cerebral cortex, report of three cases. Acta Neuropathol 42(2):127–134

    Article  CAS  PubMed  Google Scholar 

  8. Jellinger KA (2009) A critical evaluation of current staging of alpha-synuclein pathology in Lewy body disorders. Biochim Biophys Acta 1792(7):730–740

    Article  CAS  PubMed  Google Scholar 

  9. McGeer PL, McGeer EG (2008) The alpha-synuclein burden hypothesis of Parkinson disease and its relationship to Alzheimer disease. Exp Neurol 212(2):235–238

    Article  CAS  PubMed  Google Scholar 

  10. Iwai A, Masliah E, Yoshimoto M et al (1995) The precursor protein of non-a beta component of Alzheimer’s disease amyloid is a presynaptic protein of the central nervous system. Neuron 14(2):467–475

    Article  CAS  PubMed  Google Scholar 

  11. Maroteaux L, Campanelli JT, Scheller RH (1988) Synuclein: a neuron-specific protein localized to the nucleus and presynaptic nerve terminal. J Neurosci 8(8):2804–2815

    CAS  PubMed  Google Scholar 

  12. Ueda K, Fukushima H, Masliah E et al (1993) Molecular cloning of CDNA encoding an unrecognized component of amyloid in Alzheimer disease. Proc Natl Acad Sci U S A 90(23):11282–11286

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Fortin DL, Troyer MD, Nakamura K et al (2004) Lipid rafts mediate the synaptic localization of alpha-synuclein. J Neurosci 24(30):6715–6723

    Article  CAS  PubMed  Google Scholar 

  14. George JM, Jin H, Woods WS et al (1995) Characterization of a novel protein regulated during the critical period for song learning in the zebra finch. Neuron 15(2):361–372

    Article  CAS  PubMed  Google Scholar 

  15. Murphy DD, Rueter SM, Trojanowski JQ et al (2000) Synucleins are developmentally expressed, and alpha-synuclein regulates the size of the presynaptic vesicular pool in primary hippocampal neurons. J Neurosci 20(9):3214–3220

    CAS  PubMed  Google Scholar 

  16. Singleton AB, Farrer MJ, Bonifati V (2013) The genetics of Parkinson’s disease: progress and therapeutic implications. Mov Disord 28(1):14–23

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Edwards TL, Scott WK, Almonte C et al (2010) Genome-wide association study confirms SNPS in SNCA and the MAPT region as common risk factors for Parkinson disease. Ann Hum Genet 74(2):97–109

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Gandhi S, Wood NW (2010) Genome-wide association studies: the key to unlocking neurodegeneration? Nat Neurosci 13(7):789–794

    Article  CAS  PubMed  Google Scholar 

  19. Satake W, Nakabayashi Y, Mizuta I et al (2009) Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson’s disease. Nat Genet 41(12):1303–1307

    Article  CAS  PubMed  Google Scholar 

  20. Simon-Sanchez J, Schulte C, Bras JM et al (2009) Genome-wide association study reveals genetic risk underlying Parkinson’s disease. Nat Genet 41(12):1308–1312

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Singleton AB, Farrer M, Johnson J et al (2003) Alpha-synuclein locus triplication causes Parkinson’s disease. Science 302(5646):841

    Article  CAS  PubMed  Google Scholar 

  22. McNeill A, Duran R, Hughes DA et al (2012) A clinical and family history study of Parkinson’s disease in heterozygous glucocerebrosidase mutation carriers. J Neurol Neurosurg Psychiatry 83(8):853–854

    Article  PubMed  PubMed Central  Google Scholar 

  23. Danzer KM, Haasen D, Karow AR et al (2007) Different species of alpha-synuclein oligomers induce calcium influx and seeding. J Neurosci 27(34):9220–9232

    Article  CAS  PubMed  Google Scholar 

  24. Eriksen JL, Dawson TM, Dickson DW et al (2003) Caught in the act: alpha-synuclein is the culprit in Parkinson’s disease. Neuron 40(3):453–456

    Article  CAS  PubMed  Google Scholar 

  25. Savitt JM, Dawson VL, Dawson TM (2006) Diagnosis and treatment of Parkinson disease: molecules to medicine. J Clin Invest 116(7):1744–1754

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Winner B, Jappelli R, Maji SK et al (2011) In vivo demonstration that alpha-synuclein oligomers are toxic. Proc Natl Acad Sci U S A 108(10):4194–4199

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Giasson BI, Duda JE, Murray IV et al (2000) Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science 290(5493):985–989

    Article  CAS  PubMed  Google Scholar 

  28. Hunot S, Boissiere F, Faucheux B et al (1996) Nitric oxide synthase and neuronal vulnerability in Parkinson’s disease. Neuroscience 72(2):355–363

    Article  CAS  PubMed  Google Scholar 

  29. Wu DC, Teismann P, Tieu K et al (2003) Nadph oxidase mediates oxidative stress in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson’s disease. Proc Natl Acad Sci U S A 100(10):6145–6150

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Heneka MT, Kummer MP, Latz E (2014) Innate immune activation in neurodegenerative disease. Nat Rev Immunol 14(7):463–477

    Article  CAS  PubMed  Google Scholar 

  31. Shavali S, Combs CK, Ebadi M (2006) Reactive macrophages increase oxidative stress and alpha-synuclein nitration during death of dopaminergic neuronal cells in co-culture: relevance to Parkinson’s disease. Neurochem Res 31(1):85–94

    Article  CAS  PubMed  Google Scholar 

  32. Zhang W, Wang T, Pei Z et al (2005) Aggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinson’s disease. FASEB J 19(6):533–542

    Article  CAS  PubMed  Google Scholar 

  33. Braak H, Del Tredici K, Rub U et al (2003) Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 24(2):197–211

    Article  PubMed  Google Scholar 

  34. Dickson DW, Fujishiro H, Orr C et al (2009) Neuropathology of non-motor features of Parkinson disease. Parkinsonism Relat Disord 15(Suppl 3):S1–S5

    Article  PubMed  Google Scholar 

  35. Lansbury PT Jr, Brice A (2002) Genetics of Parkinson’s disease and biochemical studies of implicated gene products. Curr Opin Genet Dev 12(3):299–306

    Article  CAS  PubMed  Google Scholar 

  36. Sacchetti B, Baldi E, Lorenzini CA et al (2002) Cerebellar role in fear-conditioning consolidation. Proc Natl Acad Sci U S A 99(12):8406–8411

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Polymeropoulos MH, Lavedan C, Leroy E et al (1997) Mutation in the alpha-synuclein gene identified in families with Parkinson’s disease. Science 276(5321):2045–2047

    Article  CAS  PubMed  Google Scholar 

  38. Ross OA, Braithwaite AT, Skipper LM et al (2008) Genomic investigation of alpha-synuclein multiplication and Parkinsonism. Ann Neurol 63(6):743–750

    Article  CAS  PubMed  Google Scholar 

  39. Fleming SM, Salcedo J, Fernagut PO et al (2004) Early and progressive sensorimotor anomalies in mice overexpressing wild-type human alpha-synuclein. J Neurosci 24(42):9434–9440

    Article  CAS  PubMed  Google Scholar 

  40. Fleming SM, Tetreault NA, Mulligan CK et al (2008) Olfactory deficits in mice overexpressing human wildtype alpha-synuclein. Eur J Neurosci 28(2):247–256

    Article  PubMed  PubMed Central  Google Scholar 

  41. Lotharius J, Brundin P (2002) Pathogenesis of Parkinson’s disease: dopamine, vesicles and alpha-synuclein. Nat Rev Neurosci 3(12):932–942

    Article  CAS  PubMed  Google Scholar 

  42. Masliah E, Rockenstein E, Veinbergs I et al (2000) Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. Science 287(5456):1265–1269

    Article  CAS  PubMed  Google Scholar 

  43. Rockenstein E, Crews L, Masliah E (2007) Transgenic animal models of neurodegenerative diseases and their application to treatment development. Adv Drug Deliv Rev 59(11):1093–1102

    Article  CAS  PubMed  Google Scholar 

  44. Lace G, Savva GM, Forster G et al (2009) Hippocampal tau pathology is related to neuroanatomical connections: an ageing population-based study. Brain 132(Pt 5):1324–1334

    Article  CAS  PubMed  Google Scholar 

  45. Jellinger KA, Kovacs GG (2011) Clinico-pathological correlations in neurodegeneration. Acta Neuropathol 122(2):115–116

    Article  PubMed  Google Scholar 

  46. Lim KL, Zhang CW (2013) Molecular events underlying Parkinson’s disease – an interwoven tapestry. Front Neurol 4:33

    Article  PubMed  PubMed Central  Google Scholar 

  47. Olanow CW, Brundin P (2013) Parkinson’s disease and alpha synuclein: is Parkinson’s disease a prion-like disorder? Mov Disord 28(1):31–40

    Article  CAS  PubMed  Google Scholar 

  48. Kordower JH, Chu Y, Hauser RA et al (2008) Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson’s disease. Nat Med 14(5):504–506

    Article  CAS  PubMed  Google Scholar 

  49. Li JY, Englund E, Holton JL et al (2008) Lewy bodies in grafted neurons in subjects with Parkinson’s disease suggest host-to-graft disease propagation. Nat Med 14(5):501–503

    Article  CAS  PubMed  Google Scholar 

  50. Volpicelli-Daley LA, Luk KC, Patel TP et al (2011) Exogenous alpha-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death. Neuron 72(1):57–71

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Luk CH, Wallis JD (2009) Dynamic encoding of responses and outcomes by neurons in medial prefrontal cortex. J Neurosci 29(23):7526–7539

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Luk KC, Kehm V, Carroll J et al (2012) Pathological alpha-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science 338(6109):949–953

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Watts JC, Giles K, Oehler A et al (2013) Transmission of multiple system atrophy prions to transgenic mice. Proc Natl Acad Sci U S A 110(48):19555–19560

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Recasens A, Dehay B, Bove J et al (2014) Lewy body extracts from parkinson disease brains trigger alpha-synuclein pathology and neurodegeneration in mice and monkeys. Ann Neurol 75(3):351–362

    Article  CAS  PubMed  Google Scholar 

  55. Winblad B, Andreasen N, Minthon L et al (2012) Safety, tolerability, and antibody response of active abeta immunotherapy with cad106 in patients with Alzheimer’s disease: randomised, double-blind, placebo-controlled, first-in-human study. Lancet Neurol 11(7):597–604

    Article  CAS  PubMed  Google Scholar 

  56. Doody RS, Thomas RG, Farlow M et al (2014) Phase 3 trials of solanezumab for mild-to-moderate Alzheimer’s disease. N Engl J Med 370(4):311–321

    Article  CAS  PubMed  Google Scholar 

  57. Salloway S, Sperling R, Fox NC et al (2014) Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer’s disease. N Engl J Med 370(4):322–333

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Bae EJ, Lee HJ, Rockenstein E et al (2012) Antibody-aided clearance of extracellular alpha-synuclein prevents cell-to-cell aggregate transmission. J Neurosci 32(39):13454–13469

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Games D, Valera E, Spencer B et al (2014) Reducing c-terminal-truncated alpha-synuclein by immunotherapy attenuates neurodegeneration and propagation in Parkinson’s disease-like models. J Neurosci 34(28):9441–9454

    Article  PubMed  PubMed Central  Google Scholar 

  60. Ghochikyan A, Petrushina I, Davtyan H et al (2014) Immunogenicity of epitope vaccines targeting different b cell antigenic determinants of human alpha-synuclein: feasibility study. Neurosci Lett 560:86–91

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. Lindstrom V, Fagerqvist T, Nordstrom E et al (2014) Immunotherapy targeting alpha-synuclein protofibrils reduced pathology in (thy-1)-h[a30p] alpha-synuclein mice. Neurobiol Dis 69:134–143

    Article  PubMed  Google Scholar 

  62. Mandler M, Valera E, Rockenstein E et al (2014) Next-generation active immunization approach for synucleinopathies: implications for Parkinson’s disease clinical trials. Acta Neuropathol 127(6):861–879

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  63. Masliah E, Rockenstein E, Adame A et al (2005) Effects of alpha-synuclein immunization in a mouse model of Parkinson’s disease. Neuron 46(6):857–868

    Article  CAS  PubMed  Google Scholar 

  64. Masliah E, Rockenstein E, Mante M et al (2011) Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body disease. PLoS One 6(4):e19338

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  65. Nasstrom T, Goncalves S, Sahlin C et al (2011) Antibodies against alpha-synuclein reduce oligomerization in living cells. PLoS One 6(10):e27230

    Article  PubMed  PubMed Central  Google Scholar 

  66. Wilcock DM, Colton CA (2008) Anti-amyloid-beta immunotherapy in Alzheimer’s disease: relevance of transgenic mouse studies to clinical trials. J Alzheimers Dis 15(4):555–569

    CAS  PubMed  PubMed Central  Google Scholar 

  67. Menendez-Gonzalez M, Perez-Pinera P, Martinez-Rivera M et al (2011) Immunotherapy for Alzheimer’s disease: rational basis in ongoing clinical trials. Curr Pharm Des 17(5):508–520

    Article  CAS  PubMed  Google Scholar 

  68. Benner EJ, Banerjee R, Reynolds AD et al (2008) Nitrated alpha-synuclein immunity accelerates degeneration of nigral dopaminergic neurons. PLoS One 3(1), e1376

    Article  PubMed  PubMed Central  Google Scholar 

  69. Reynolds AD, Stone DK, Hutter JA et al (2010) Regulatory t cells attenuate th17 cell-mediated nigrostriatal dopaminergic neurodegeneration in a model of Parkinson’s disease. J Immunol 184(5):2261–2271

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  70. Sanchez-Guajardo V, Barnum CJ, Tansey MG et al (2013) Neuroimmunological processes in Parkinson’s disease and their relation to alpha-synuclein: microglia as the referee between neuronal processes and peripheral immunity. ASN Neuro 5(2):113–139

    Article  CAS  PubMed  Google Scholar 

  71. Reynolds AD, Stone DK, Mosley RL et al (2009) Nitrated {alpha}-synuclein-induced alterations in microglial immunity are regulated by cd4+ t cell subsets. J Immunol 182(7):4137–4149

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  72. Sanchez-Guajardo V, Annibali A, Jensen PH et al (2013) Alpha-synuclein vaccination prevents the accumulation of Parkinson disease-like pathologic inclusions in striatum in association with regulatory t cell recruitment in a rat model. J Neuropathol Exp Neurol 72(7):624–645

    Article  CAS  PubMed  Google Scholar 

  73. Wiessner C, Wiederhold KH, Tissot AC et al (2011) The second-generation active abeta immunotherapy cad106 reduces amyloid accumulation in app transgenic mice while minimizing potential side effects. J Neurosci 31(25):9323–9331

    Article  CAS  PubMed  Google Scholar 

  74. Schneeberger A, Mandler M, Mattner F et al (2010) Affitome(r) technology in neurodegenerative diseases: the doubling advantage. Hum Vaccin 6(11):948–952

    Article  CAS  PubMed  Google Scholar 

  75. Schneeberger A, Mandler M, Mattner F et al (2012) Vaccination for Parkinson’s disease. Parkinsonism Relat Disord 18(Suppl 1):S11–S13

    Article  PubMed  Google Scholar 

  76. Abeliovich A, Schmitz Y, Farinas I et al (2000) Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron 25(1):239–252

    Article  CAS  PubMed  Google Scholar 

  77. Hashimoto M, Rockenstein E, Mante M et al (2001) Beta-synuclein inhibits alpha-synuclein aggregation: a possible role as an anti-parkinsonian factor. Neuron 32(2):213–223

    Article  CAS  PubMed  Google Scholar 

  78. Hashimoto M, Kawahara K, Bar-On P et al (2004) The role of alpha-synuclein assembly and metabolism in the pathogenesis of Lewy body disease. J Mol Neurosci 24(3):343–352

    Article  CAS  PubMed  Google Scholar 

  79. Biere AL, Wood SJ, Wypych J et al (2000) Parkinson’s disease-associated alpha-synuclein is more fibrillogenic than beta- and gamma-synuclein and cannot cross-seed its homologs. J Biol Chem 275(44):34574–34579

    Article  CAS  PubMed  Google Scholar 

  80. Fan Y, Limprasert P, Murray IV et al (2006) Beta-synuclein modulates alpha-synuclein neurotoxicity by reducing alpha-synuclein protein expression. Hum Mol Genet 15(20):3002–3011

    Article  CAS  PubMed  Google Scholar 

  81. Lee HJ, Khoshaghideh F, Patel S et al (2004) Clearance of alpha-synuclein oligomeric intermediates via the lysosomal degradation pathway. J Neurosci 24(8):1888–1896

    Article  CAS  PubMed  Google Scholar 

  82. Tran HT, Chung CH, Iba M et al (2014) Alpha-synuclein immunotherapy blocks uptake and templated propagation of misfolded alpha-synuclein and neurodegeneration. Cell Rep 7(6):2054–2065

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  83. Fagerqvist T, Lindstrom V, Nordstrom E et al (2013) Monoclonal antibodies selective for alpha-synuclein oligomers/protofibrils recognize brain pathology in Lewy body disorders and alpha-synuclein transgenic mice with the disease-causing a30p mutation. J Neurochem 126(1):131–144

    Article  CAS  PubMed  Google Scholar 

  84. Lindstrom V, Ihse E, Fagerqvist T et al (2014) Immunotherapy targeting alpha-synuclein, with relevance for future treatment of Parkinson’s disease and other Lewy body disorders. Immunotherapy 6(2):141–153

    Article  PubMed  Google Scholar 

  85. Leber P (1997) Slowing the progression of Alzheimer disease: methodologic issues. Alzheimer Dis Assoc Disord 11(Suppl 5):S10–S21, Discussion S37-19

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. AFFiRiS AG, Karl-Farkas Gasse 22, 1030, Vienna, Austria

    Achim Schneeberger & Markus Mandler

  2. Pentara Corporation, Salt Lake City, UT, USA

    Suzanne Hendrix

Authors
  1. Achim Schneeberger
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Suzanne Hendrix
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Markus Mandler
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Achim Schneeberger .

Editor information

Editors and Affiliations

  1. Dept Public Health & Caring Sci Ger, Uppsala University, Uppsala, Sweden

    Martin Ingelsson

  2. Dept Public Health & Caring Sci Ger, Uppsala University, Uppsala, Sweden

    Lars Lannfelt

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer Science+Business Media New York

About this protocol

Cite this protocol

Schneeberger, A., Hendrix, S., Mandler, M. (2016). Immunotherapy of Parkinson’s Disease. In: Ingelsson, M., Lannfelt, L. (eds) Immunotherapy and Biomarkers in Neurodegenerative Disorders. Methods in Pharmacology and Toxicology. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-3560-4_7

Download citation

  • DOI: https://doi.org/10.1007/978-1-4939-3560-4_7

  • Published:

  • Publisher Name: Humana Press, New York, NY

  • Print ISBN: 978-1-4939-3558-1

  • Online ISBN: 978-1-4939-3560-4

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics

Search

Navigation